Does Anthem Cover Zepbound for Weight Loss? Honest Evidence Review

Short version: most Anthem commercial fully-insured plans DO cover Zepbound for weight loss — with prior authorization, a BMI threshold, a documented 3-to-6-month lifestyle program, and usually a Wegovy-first step-therapy requirement on the formulary codes where CarelonRx has named Wegovy the preferred agent. Anthem Medicare Advantage plans do NOT cover Zepbound for weight loss (federal Part D exclusion) but DO cover Zepbound for the separate FDA-approved obstructive sleep apnea indication. Self-funded employer (ASO) plans can opt out of weight-loss drug coverage entirely — that's an employer decision, not Anthem's. Below we cite the exact Anthem criteria document, the federal exclusion statute, and the FDA label that makes the OSA pathway covered.

At a glance

• Anthem commercial fully-insured: generally YES with prior authorization. Typical copay with PA approved is roughly $25-$100/month depending on the formulary tier.^[1]
• Anthem self-funded employer (ASO): depends entirely on the employer. Many employers exclude weight-loss drug coverage even when the Anthem commercial formulary includes Zepbound. Ask HR or Benefits.
• Anthem Medicare Advantage: NO for weight-loss-only Zepbound — federal Part D excludes agents “when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain.”^[5] YES for the separate FDA-approved moderate-to-severe obstructive sleep apnea indication (approved 12/20/2024).^[4][6]
• Anthem Medicaid: varies dramatically by state. Virginia (Anthem HealthKeepers Plus) requires BMI >40 (or >37 with dyslipidemia/HTN).^[3] California (Anthem Blue Cross Medi-Cal) removed weight-loss GLP-1 coverage effective 01/01/2026.^[2]
• Typical PA criteria: BMI ≥30 OR BMI ≥27 with a weight-related comorbidity (HTN, T2D, dyslipidemia, OSA), age 18+, documented behavioral and dietary program (3 months minimum per CC-0188; many plans require 6 months).^[1]
• Step therapy: on most plan formularies administered by CarelonRx, Wegovy is the preferred GLP-1 for weight management — Zepbound requires either a Wegovy trial first OR a documented intolerance/contraindication.
• Medicare GLP-1 Bridge (07/01/2026 - 12/31/2027): Anthem MA-PD members get time-limited Zepbound coverage at $50/month flat — but only the Zepbound KwikPen formulation, not vials or single-dose pens. Eligibility: BMI ≥27 plus heart disease or prediabetes.^[7]

Anthem commercial fully-insured plans — covered with PA

Anthem's Medical Drug Clinical Criteria CC-0188 governs weight-management-agent prior authorization across Wegovy, Zepbound, and Saxenda for commercially insured members (non-Medicare, non-Medicaid).^[1] The adult initial criteria distilled from the published document:

• Age 18 or older.
• BMI ≥ 30 kg/m², OR BMI ≥ 27 kg/m² with at least one weight-related comorbid condition (hypertension, type 2 diabetes mellitus, dyslipidemia, or — post-12/20/2024 — moderate-to-severe obstructive sleep apnea).
• Documented participation in a behavioral and dietary program (the CC-0188 framework specifies a 3-month minimum; individual Anthem state subsidiaries and employer groups frequently impose a 6-month requirement that mirrors the Aetna 4774-C structure — confirm with your specific plan).
• Continuation/reauthorization requires documented weight loss of approximately 5% from baseline (the canonical threshold carried across the FDA label, commercial PA bulletins, and ACC/AHA obesity-medicine guidance).

Typical out-of-pocket once PA is approved: on a commercial Anthem plan with Zepbound on a preferred specialty or non-preferred brand tier, copays generally fall between $25 and $100/month. The Lilly Zepbound Savings Card (for commercially insured patients with coverage) can reduce out-of-pocket to as low as $25/month for eligible members. For commercial plans where Zepbound is non-preferred and Wegovy is preferred (most plans, see step therapy below), the savings card combined with formulary tiering is usually the lowest-cost path.

Anthem self-funded employer (ASO) plans — employer decides

This is the single biggest source of confusion. A large fraction of Anthem-branded plans are self-funded (also called “ASO” — Administrative Services Only). The employer pays claims directly from a corporate health trust; Anthem just rents out its provider network, claims-processing infrastructure, and pharmacy benefit manager (CarelonRx). On these plans the employer chooses whether to cover weight-loss drugs at all.

Even if Anthem's commercial formulary lists Zepbound as covered with PA, your specific self-funded employer can carve out anti-obesity medications as a non-covered benefit class — and many do, citing the cost. KFF and Mercer employer-survey data through 2025 showed roughly half of large self-funded employers excluded GLP-1 weight-loss agents from their benefits design.

How to tell if your Anthem plan is self-funded: ask HR or look at your Summary Plan Description (SPD) — it will say “self-insured” or “fully insured” somewhere in the plan-administration section. The SPD for a self-funded plan also typically lists the employer (not Anthem) as the “Plan Sponsor.” If self-funded, your appeals path goes through ERISA (federal law) and your employer's plan administrator — not through Anthem's state-insurance external review.

Anthem Medicare Advantage — NO for weight loss, YES for sleep apnea

Anthem Medicare Advantage plans operate under federal Medicare Part D rules. Social Security Act §1860D-2(e)(2)(A) explicitly excludes “agents when used for anorexia, weight loss, or weight gain” from Part D coverage.^[5] This statutory exclusion is why no Medicare plan — Anthem MA-PD or otherwise — covers Zepbound for weight-loss-only indications today.

The sleep-apnea exception: on December 20, 2024, the FDA approved Zepbound as the first medication ever approved for moderate-to-severe obstructive sleep apnea in adults with obesity.^[6] The Zepbound DailyMed label (SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b, label updated 04/22/2026) lists the second indication verbatim as: “to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.”^[4] Because OSA is a distinct FDA-approved indication — not weight loss — the §1860D-2(e)(2)(A) Part D exclusion does NOT apply, and Anthem MA-PD plans can cover Zepbound for OSA subject to PA. The SURMOUNT-OSA trial (Malhotra et al., NEJM 2024, PMID 38912654) is the underlying evidence base.^[10] For the full clinical picture, see our SURMOUNT-OSA tirzepatide / sleep apnea evidence article.

The Medicare GLP-1 Bridge (07/01/2026 onward): a separate time-limited federal program creates a coverage path for Wegovy (all formulations), Zepbound KwikPen only (NOT vials or single-dose pens), and Foundayo for Anthem MA-PD members with BMI ≥27 plus heart disease or prediabetes. Copay is $50/month flat. The bridge runs through 12/31/2027 and the $50 copay does NOT count toward the deductible or the $2,100 out-of-pocket cap.^[7]

Anthem Medicaid — state-by-state, wildly variable

Anthem operates Medicaid managed-care plans under different brands in different states (HealthKeepers Plus in Virginia, Anthem Blue Cross Medi-Cal in California, Anthem Blue Cross and Blue Shield Medicaid in Indiana, Kentucky, Nevada, New Hampshire, Ohio, and Wisconsin). State Medicaid PDLs (Preferred Drug Lists) supersede everything in CC-0188 for Medicaid members. Two illustrative extremes:

• Virginia (Anthem HealthKeepers Plus): Weight-Loss Management PA Form requires BMI > 40 kg/m² (no comorbidity required) OR BMI > 37 kg/m² with dyslipidemia or hypertension. This is the highest published BMI threshold among the commercial PA triplet.^[3]
• California (Anthem Blue Cross Medi-Cal): per provider notice 11/14/2025, weight-loss GLP-1 coverage (Wegovy, Zepbound, Saxenda) was removed effective January 1, 2026. MACE (Wegovy) and the MASH indication (re-added 04/01/2026) remain coverable, but weight-loss-only Zepbound is no longer a Medi-Cal benefit in California.^[2]

For an exhaustive state breakdown and the Medicare/commercial/ FEHB/Tricare/VA landscape, see our GLP-1 insurance coverage landscape article.

Step therapy: Wegovy first, Zepbound on appeal

CarelonRx — Anthem's wholly owned PBM (formerly IngenioRx, rebranded in 2023) — has designated Wegovy as the preferred weight-loss GLP-1 on most Anthem commercial formularies. This creates a Zepbound step-therapy requirement structurally similar to the CVS Caremark / Aetna dynamic documented in our Aetna GLP-1 PA guide: the patient is expected to try Wegovy first and demonstrate either inadequate response, intolerance, or contraindication before Zepbound is approved.

Acceptable Wegovy-failure documentation typically includes:

• < 5% baseline weight loss after a documented Wegovy trial at the maintenance dose (2.4 mg weekly, typically 16+ weeks).
• Persistent intolerable adverse effects on Wegovy that did not resolve with dose adjustment (severe nausea, vomiting, injection-site reactions).
• A contraindication to semaglutide that does not apply to tirzepatide (rare — both share the personal/family history of medullary thyroid carcinoma and MEN-2 boxed warnings).

For the operational deep-dive — including the CC-0188 verbatim clauses, CarelonRx PBM dynamics, the 14-state Blue Cross Blue Shield subsidiary variation, and the appeal pathway through Anthem's external review — see our Anthem GLP-1 prior-authorization guide (the operational sibling to this YES/NO coverage answer).

What to do if Anthem denies your Zepbound PA

The Anthem appeals process gives commercial members 180 days from the denial notice to file a written internal appeal. The sequence:

1. Get the written denial letter. It will name the specific clause your submission failed (BMI threshold, missing lifestyle-program documentation, step therapy not satisfied, formulary tier exception not requested, etc.).
2. Identify the actual problem. The single most common Zepbound denial reason in 2026 is the Wegovy-first step requirement on CarelonRx-administered formularies. The second-most-common is missing 3-to-6-month lifestyle-program documentation.
3. File an internal appeal with a Letter of Medical Necessity. Include baseline BMI, comorbidity documentation (HTN, T2D, dyslipidemia, or OSA diagnosis), the dated lifestyle-program records, and — if step therapy is the issue — explicit documentation of Wegovy intolerance, inadequate response, or contraindication.
4. If the internal appeal is denied, request an external review through Anthem's independent review organization (commercial fully-insured plans) OR through your state insurance department (some states require routing through them). External-review decisions are binding on commercial plans. For ERISA self-funded plans, the appeal goes through your employer's plan administrator and the U.S. Department of Labor — not Anthem.

Switching from Wegovy to Zepbound on Anthem

If you started on Wegovy under Anthem coverage and want to switch to Zepbound, the clean clinical-failure pathway is:

• Complete a documented Wegovy trial at the maintenance dose (2.4 mg weekly, minimum 16 weeks per most Anthem-affiliated PA frameworks).
• Document < 5% baseline weight loss at the milestone check, OR document specific intolerable adverse effects that persisted through dose adjustment.
• Have your prescriber submit a new PA for Zepbound under CC-0188, citing the Wegovy failure as the step-therapy satisfaction.
• For the dose-equivalence picture (Wegovy 2.4 mg ≈ Zepbound 5-10 mg starting territory), see our Wegovy → Zepbound switch dose-equivalence guide.

If Anthem denies — alternatives that actually work

While the appeal is in flight, the practical alternatives ranked by cost:

• Compounded tirzepatide via verified 503A telehealth — typical $149-$349/month. Not brand Zepbound (the active pharmaceutical ingredient is the same, but quality and supply-chain rigor vary widely across compounding pharmacies). See our where-to-buy tirzepatide guide for the verified-provider directory.
• LillyDirect Self Pay Pharmacy single-dose vials — $299/month (2.5 mg) → $399 (5 mg) → $499 (7.5 mg) → $699 (10/12.5/15 mg) as of the December 1, 2025 price reduction. The Self Pay Journey Program at $449/month is available to eligible patients on the 7.5 mg dose and above.^[11]
• Retail-pharmacy brand Zepbound autoinjector — list price typically $1,000-$1,300/month depending on dose. Avoid this path unless absolutely necessary; LillyDirect vials at the same effective dose are roughly half the cost.
• Wait for Medicare GLP-1 Bridge (07/01/2026) — for Anthem MA-PD members with BMI ≥27 plus heart disease or prediabetes. $50/month flat copay through 12/31/2027. Zepbound KwikPen only; vials and single-dose pens are NOT in the bridge.^[7]

For mechanism-of-action context (SURMOUNT-1 demonstrated ~20.9% body-weight reduction at 72 weeks on tirzepatide 15 mg^[8]; SURMOUNT-2 confirmed efficacy in T2D +obesity^[9]), see our tirzepatide vs semaglutide head-to-head article.

Verdict — what most Anthem members should expect

For the majority of Anthem-insured patients asking does Anthem cover Zepbound for weight loss: yes, on a commercial fully-insured plan, with prior authorization, a BMI ≥30 (or ≥27 with comorbidity), a documented lifestyle program, and frequently a Wegovy-first step therapy. Expected out-of-pocket after PA approval is $25-$100/month depending on the formulary tier and savings-card eligibility.

The exceptions are the load-bearing details — verify all three before committing to a treatment plan:

1. Is your plan self-funded? If yes, ask HR whether weight-loss medications are a covered benefit class. Anthem's commercial formulary tells you nothing if your employer carved them out.
2. Are you on Anthem Medicare Advantage? If yes, weight-loss-only Zepbound is NOT covered today. Sleep-apnea Zepbound IS covered post-12/20/2024 if you have a moderate-to-severe OSA diagnosis. The Medicare GLP-1 Bridge (07/01/2026 - 12/31/2027) opens a third path.
3. Are you on Anthem Medicaid? Your state PDL supersedes CC-0188. California Medi-Cal removed weight-loss GLP-1 coverage effective 01/01/2026; Virginia HealthKeepers Plus requires BMI > 40. Check your state.

For the side-effect picture once coverage is sorted, see our GLP-1 side-effect questions hub — the most-asked questions from active GLP-1 users with primary-source answers. For drug-specific reference data, see the Zepbound drug page and the tirzepatide active-ingredient page.